Technical Analysis for MLLCF - Molecular Partners Ag

Grade Last Price % Change Price Change
grade D 14.1 -0.21% -0.0300
MLLCF closed down 0.21 percent on Friday, July 19, 2019, on 7 percent of normal volume. The bears made the stock sink to a new 52-week low.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Down
See historical MLLCF trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
Hot IPO Pullback Bullish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
New 52 Week Low Weakness 0.00%
Gapped Down Weakness 0.00%
New 52 Week Closing Low Bearish -0.21%
Narrow Range Bar Range Contraction -0.21%
New 52 Week Low Weakness -0.21%
Gapped Down Weakness -0.21%
Narrow Range Bar Range Contraction -4.51%

Older signals for MLLCF ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Molecular Partners AG, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of various biopharmaceutical products. It is developing Abicipar, a DARPin-based anti-angiogenic drug, which is in Phase III clinical trials for the treatment of wet age-related macular degeneration and diabetic macular edema diseases, as well as on a partnered pipeline that includes novel approaches to the treatment of severe ocular diseases. The company also develops MP0250, which is in Phase I clinical studies for the treatment of solid tumor cancers and hematological malignancies; and MP0274 that is in preclinical studies for the treatment of breast cancer. The company has strategic partnerships with Allergan, Inc.; Janssen Biotech, Inc.; and Amgen SA. Molecular Partners AG was founded in 2004 and is based in Schlieren, Switzerland.
Medicine Health Clinical Medicine Biopharmaceutical Breast Cancer Monoclonal Antibodies Diabetic Retinopathy Biopharmaceutical Products Macular Edema Wet Age Related Macular Degeneration Solid Tumor Cancers Treatment Of Breast Cancer Amgen Breakthrough Therapy Hematological Malignancies
Is MLLCF a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Indicators
Indicator Value
52 Week High 22.0845
52 Week Low 14.1
Average Volume 1,452
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 17.0909
Average True Range 0.0
ADX 0.0
+DI 0.0
-DI 0.0
Chandelier Exit (Long, 3 ATRs ) N/A
Chandelier Exit (Short, 3 ATRs ) N/A
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.0
MACD Signal Line 0.0
MACD Histogram 0.0
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 14.1000
Resistance 3 (R3) 14.1000 14.1000 14.1000
Resistance 2 (R2) 14.1000 14.1000 14.1000 14.1000
Resistance 1 (R1) 14.1000 14.1000 14.1000 14.1000 14.1000
Pivot Point 14.1000 14.1000 14.1000 14.1000 14.1000
Support 1 (S1) 14.1000 14.1000 14.1000 14.1000 14.1000
Support 2 (S2) 14.1000 14.1000 14.1000 14.1000
Support 3 (S3) 14.1000 14.1000 14.1000
Support 4 (S4) 14.1000